0,1
"6.1.6	
General guidelines for the treatment of prostate cancer*",
Recommendations,Strength rating
"Base follow-up during active surveillance (AS) on a strict protocol including digital rectal 
examination (at least once yearly), prostate-specific antigen (PSA) (at least once every  
6 months) and repeated biopsy every 2 to 3 years.",Strong
"Perform magnetic resonance imaging (MRI) and repeat biopsy if PSA is rising (PSA-doubling 
time < 3 years).",Strong
"Re-classify patients with low-volume ISUP grade group 2 disease included in AS protocols, 
if repeat non-MRI-based systematic biopsies performed during monitoring reveal > 3 
positive cores or maximum CI > 50%/core of ISUP 2 disease.",Weak
"Base change in treatment on biopsy progression, not on progression on MRI and/or PSA.",Weak
"Patients with a PI-RADS 1-2 findings on MRI and a low PSA density (< 0.15) may be 
excepted from repeat biopsy.",Weak
